The Life Sciences team advised argenx SE (Euronext & Nasdaq: ARGX) on its $862.5 million global offering of an aggregate of 4,207,292 ordinary shares (including ordinary shares represented by American Depository Shares (ADSs)), which included the full exercise of the underwriters’ option to purchase additional ADSs. The offering consisted of (i) a public offering of ADSs in the United States and certain other countries outside the European Economic Area at a price of $205.00 per share and (ii) a concurrent private placement of ordinary shares in the European Economic Area at a price of approximately €186.52 per share.
argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. By translating immunology breakthroughs into innovative drug candidates, argenx is building a world-class portfolio of first-in-class antibodies in both early and late clinical stages of development.
The Goodwin team was led by Michael Bison and Edwin O’Connor and included Janet Andolina, Duncan Greenhalgh, Olivia Uitto, and Ettore Santucci.
For more details, read the press release and articles in Reuters and LaBiotech.eu.